BioSyent Q2 FY26 net income rises 41% to CAD 2.85 million; net revenues more than double to CAD 19.87 million

• BioSyent posted Q2 net sales of CAD 19.87 million, up 95% from Q2 2025; EBITDA rose 80% to CAD 4.98 million.
• Net income after tax climbed 41% to CAD 2.85 million; fully diluted EPS increased 39% to CAD 0.25.
• H1 net sales jumped 60% to CAD 33.78 million; EBITDA advanced 45% to CAD 8.62 million.
• H1 net income after tax rose 20% to CAD 5.19 million; fully diluted EPS grew 19% to CAD 0.45.
• Results reflect the first full quarter from the Oral Health segment, delivering Q2 sales of CAD 8.22 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioSyent Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608201700PRIMZONEFULLFEED9813557) on August 20, 2026, and is solely responsible for the information contained therein.